- Home
- GILT vs KALV Comparison
GILT vs KALV Comparison
Compare GILT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- KALV
- Stock Information
- Founded
- GILT 1987
- KALV N/A
- Country
- GILT Israel
- KALV United States
- Employees
- GILT N/A
- KALV N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- KALV Health Care
- Exchange
- GILT Nasdaq
- KALV Nasdaq
- Market Cap
- GILT 894.0M
- KALV 796.4M
- IPO Year
- GILT 1993
- KALV N/A
- Fundamental
- Price
- GILT $13.88
- KALV $10.97
- Analyst Decision
- GILT Strong Buy
- KALV Strong Buy
- Analyst Count
- GILT 2
- KALV 8
- Target Price
- GILT $11.00
- KALV $26.43
- AVG Volume (30 Days)
- GILT 1.1M
- KALV 1.5M
- Earning Date
- GILT 11-12-2025
- KALV 09-11-2025
- Dividend Yield
- GILT N/A
- KALV N/A
- EPS Growth
- GILT 12.49
- KALV N/A
- EPS
- GILT 0.39
- KALV N/A
- Revenue
- GILT $349,746,000.00
- KALV $1,426,000.00
- Revenue This Year
- GILT $47.18
- KALV N/A
- Revenue Next Year
- GILT $13.80
- KALV $213.43
- P/E Ratio
- GILT $36.14
- KALV N/A
- Revenue Growth
- GILT 19.67
- KALV N/A
- 52 Week Low
- GILT $4.83
- KALV $7.30
- 52 Week High
- GILT $14.65
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- GILT 73.53
- KALV 32.68
- Support Level
- GILT $13.40
- KALV $11.93
- Resistance Level
- GILT $12.45
- KALV $12.04
- Average True Range (ATR)
- GILT 0.56
- KALV 0.56
- MACD
- GILT 0.14
- KALV -0.21
- Stochastic Oscillator
- GILT 77.33
- KALV 10.10
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.